Futura Medical PLC (AIM:FUM, OTC:FAMDF) Head of R&D Ken James joined Steve Darling from Proactive to share the company’s latest developments in sexual health solutions. Futura’s flagship product, Eroxon, is a topical gel for erectile dysfunction (ED) that offers a rapid onset in under 10 minutes, setting it apart from traditional oral medications. “Eroxon has a very, very good side effect profile,” noted James, highlighting its suitability as an over-the-counter option for ED.
In response to consumer demand, Futura is developing an enhanced version called Eroxon Intense, catering to users seeking a stronger effect. This approach aligns with common consumer healthcare strategies, such as variations in pain relief formulations, allowing the company to meet diverse customer needs. In addition to Eroxon, Futura is working on an innovative product targeting female sexual dysfunction—a pressing yet often overlooked need, especially post-menopause, affecting up to 50% of women according to research. This female-focused product is showing promising early study results, and Futura plans to advance to broader trials and engage with the U.S. FDA for over-the-counter approval. With ongoing global partnerships and active engagement with regulatory authorities, Futura aims to establish a significant presence in both the male and female sexual health markets.
These advancements are backed by extensive research and a solid financial foundation, positioning Futura as a leader in addressing critical gaps in sexual health solutions.
